EZH2 and glioma: The EZH2/miR-328/β-catenin signaling cascade serves as a novel therapeutic biomarker for glioma, whereas inhibition of EZH2 is also associated with the suppression of glioma growth by restraining the β-catenin signaling pathway [19].